TrialSchizophrenia bulletin2019

Evaluation of the Efficacy, Safety, and Tolerability of BI 409306, a Novel Phosphodiesterase 9 Inhibitor, in Cognitive Impairment in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled, Phase II Trial.

David Brown et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.